PARTHENOLIDE REDUCES GENE TRANSCRIPTION OF PROSURVIVAL MEDIATORS IN U937 CELLS

S. Mohammadi\textsuperscript{1}, M. Zahedpanah\textsuperscript{2, *}, M. Nikbakht\textsuperscript{1}, M. Shaiegan\textsuperscript{3}, S. Hamidollah Ghaffari\textsuperscript{4}, M. Nikugoftar\textsuperscript{5}, B. Rahmani\textsuperscript{2}, D. Hamedi Asl\textsuperscript{6}

\textsuperscript{1}Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran 14176–13151, Iran

\textsuperscript{2}Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Qazvin University of Medical Sciences, Qazvin 34157–38477, Iran

\textsuperscript{3}Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran 14665–1157, Iran

\textsuperscript{4}Department of Biochemistry and Genetics, Qazvin University of Medical Sciences, Qazvin 34157–38477, Iran

Submitted: August 22, 2016.

*Correspondence: E-mail: zhdpnh@yahoo.com

\textsuperscript{*}Abbreviations used: AML – acute myeloid leukemia; OPN – osteopontin; PI3K – phosphoinositide 3-kinase; PTL – parthenolide.

The varying response of acute myeloid leukemia (AML) cells to apoptosis-inducing agents reflects the heterogeneous biological nature of AML [1]. Generally, an apoptosis evasion can be achieved by activating anti-apoptotic molecules. Phosphoinositide 3-kinases (PI3Ks) regulate a variety of important cellular functions, such as growth, cell cycle progression, apoptosis. Human leukemic cells display abnormal regulation of crucial factor in PI3Ks pathway, which will be useful to interpret the mechanisms of resistance to the conventional class of chemotherapeutic agents [2].

The functional abnormalities of osteopontin (OPN), nuclear factor-κB (NF-κB), PI3K/AKT/mTOR/PTEN pathway or β-catenin have been considered. \textit{Aim: To analyze the response of U937 cells to parthenolide (PTL)} through the involvement of expression of OPN protein, RelB, AKT1, mTOR, PTEN and β-catenin genes.

Materials and Methods: The U937 cells were treated with PTL at concentrations of 4 μM (IC25) or 6 μM (IC50) and with OPN siRNA for MTT assay and colony forming assay. Western blot analysis using antibodies against OPN was performed with lysates of PTL-treated cells. Quantitative real-time polymerase chain reaction was performed using primers for OPN, RelB, AKT1, mTOR, PTEN and β-catenin. Results: PTL reduces OPN protein level and down-regulates RelB mRNA in U937 cell line. Suppression of OPN with siRNA increases the cytotoxic effects of PTL. Also, mRNA expression of AKT1, mTOR, PTEN, and β-catenin decreases with PTL or OPN siRNA.

Conclusion: Sensitivity of U937 cells to PTL can be associated with the reduction in expression of prosurvival mediators.

Key Words: parthenolide, osteopontin, RelB, AKT1, mTOR, β-catenin, U937 cells.
tosis in leukemic cells [18–20]. PTL exerts apoptosis, inhibition of cell proliferation or antitumor activity either through NF-kB inhibition and/or possibly by other mechanisms [20, 21] including activation suppression of Akt and mTOR [22], blocking of STAT3 activity [23] and increase in reactive oxygen species [24].

In the present study, we tried to analyze the response of myelomonocytic leukemic U937 cells [25] to PTL through expression of cytotoxic mediator OPN protein, RelB, AKT1, mTOR, PTEN and β-catenin genes. In addition, we examined whether inhibition of OPN mRNA can affect the viability, proliferation, and transcription of the above-mentioned pro-survival genes in U937 cells.

**MATERIALS AND METHODS**

**Reagents.** PTL purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO) was dissolved in dimethyl sulfoxide (DMSO) as a 50 mM stock solution, stored at −20 °C and diluted in the distilled water prior to use. The IgG2a mouse anti-human OPN and mouse anti-human β-actin monoclonal antibodies, as well as the horseradish peroxidase-conjugated secondary goat anti-mouse IgG antibody were purchased from R&D Systems (R&D System, Minneapolis, MN). TriPure isolation Reagent was purchased from Roche Applied Science (Penzberg, Germany). The cDNA synthesis kit and SYBR® Premix Ex Taq™ were purchased from Takara Biotechnology Co (Otsu, Japan).

**Cell culture.** The human myelomonocytic leukemic U937 cell line was obtained from the Pasteur Institute of Iran and cultured in RPMI 1640 with 10% FBS (Gibco, Carlsbad, CA). The medium were supplemented with 2 mM L-glutamine, 100 units/ml penicillin and 100 μg/ml streptomycin. Cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2.

**MTT assays.** U937 cells were cultured in triplicate at 5–10⁶/100 μl in 96-well culture plates (SPL Life sciences, Pocheon, Korea). The cells were treated with different concentrations of PTL based on determined IC₅₀ or IC₃₀ in our previous study [26]. After incubation (37 °C, 5% CO₂), the cells were incubated for 4 h with 3–(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ml) (Sigma-Aldrich, St Louis, MO). The plates were spun, and the purple formazan crystals of yellow tetrazolium salt metabolized by viable cells were dissolved in DMSO. Absorbance was quantified at 570 nm using the ELISA plate reader (Miroplate Reader; Bio-Rad, USA). Results were expressed as a percentage of viability, with 100% representing control cells treated with 0.1% DMSO alone.

**Colony forming assay.** U937 cells were suspended at a density of 2000 cells in 0.5 ml of RPMI 1640, and then treated with PTL alone or simultaneously in combination with OPN siRNA. The treated and untreated cell line were plated in Methocult semisolid medium (Stem Cell Technologies, Vancouver, BC, Canada). After 14–16 days incubation, the colonies were enumerated by inverted microscope. Accumulation of >50 cells was scored as granulocyte-macrophage colony-forming units and collection of 3–50 cells was considered as one cluster. Three independent experiments were performed.

**Western blotting analysis.** The cells (1·10⁶ cells/ml) were incubated with 4 μmol/l PTL for 24 h. Then cells were lysed in the lysis buffer containing 1.0% Nonidet P-40, 150 mM NaCl, 20 mM Tris-HCl (pH 7.5), 5 mM EDTA, and a protease inhibitor mixture tablet Complete (Roche Diagnostics, Indianapolis, IN). Extracted proteins (60 μg) were loaded on SDS-PAGE and transferred on PVDF Membrane (Roche). After that the membranes were blocked by skimmed milk (Merck) and immunoblotted with mouse anti-human OPN and mouse anti-human β-actin antibodies. Membranes were visualized using an appropriate horseradish peroxidase-conjugated secondary antibody and enhanced chemiluminescence Western blotting detection system (Roche Diagnostics, Indianapolis, IN).

**Quantitative real-time polymerase chain reaction (qRT-PCR).** Total RNA of the PTL-treated and untreated cell line was extracted with TriPure isolation reagent according to the manufacturer’s instruction. The cDNA synthesis kit was used for complementary DNA (cDNA) synthesis. A light cycler instrument (Roche Diagnostic, Manheim, Germany) and SYBR® Premix Ex Taq™ were used for quantitative real-time analysis. A final volume of 20 μl containing 2 μl of a 2-fold diluted cDNA, 1 μl of 10 pmol primers (0.5 μl each forward and reverse primers), 10 μl of SYBER and 7 μl distilled water were used. Data were normalized to HPRT expression in each sample. Analysis of relative gene expression data were performed using the 2⁻ΔΔCT method. The Table shows the primer sequences for genes used.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5'→3')</th>
<th>Reverse primer (5'→3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPRT</td>
<td>TGGACAGGCACTGACCTGTCG</td>
<td>CCAGCAAGGTCGACAAAGATTTA</td>
</tr>
<tr>
<td>OPN</td>
<td>ACCCTTCCTAGAATCCCAACCG</td>
<td>GGTGGAATATCAGTCAGTCATCAC</td>
</tr>
<tr>
<td>NF-B/RelB</td>
<td>GCCTGACCCCTTGGGACTGTTA</td>
<td>CTAGATGACGCGCTGTCGTGTC</td>
</tr>
<tr>
<td>AKT1</td>
<td>AGCCATGGGCTTGGTAGAAGAG</td>
<td>CAGTCCCTTGGCTTGTTGCGAG</td>
</tr>
<tr>
<td>mTOR</td>
<td>AAGTCGCCGAGAAGTACGCAAGA</td>
<td>AGTGTGCTGATAGAAGCCTAGGAG</td>
</tr>
<tr>
<td>PTEN</td>
<td>TGGATGCAGCTGAGCTGAGCCT</td>
<td>TTGCGGCTGGTCACAGAGCTGTT</td>
</tr>
<tr>
<td>β-Catenin</td>
<td>TACCTCCCCAGGTCGGATGAGGGA</td>
<td>TGACGAGCAGCACAAGCTGAGT</td>
</tr>
</tbody>
</table>

**RNA interfering.** The siRNA against OPN was applied to PTL-treated cells using lipofectamin 2000 reagent (LF2000; 10 μg/ml; Invitrogen), according to the manufacturer’s instruction. Cells were lysed 24 h post-transfection and quantitative real-time RT-PCR was performed using following sequences of OPN siRNA primers: 5′-CCACGAGUAAGUCACAGAAA (dTdT)-3′ (sense) and 5′-UUCGGUUGACUCAUCUUGG (dTdT)-3′ (anti-sense). Highest transfection efficiency with minimal effects on cell viability was obtained in optimization experiments within 24 h post-transfection at a final concentration 40 pmol/ml and we used these optimal conditions for subsequent experiments with test siRNAs.

**Statistical analysis.** Using IBM SPSS Statistics 19 software the groups of data were presented as means ± SD and compared by one-way analysis of variance (ANOVA).
RESULTS

**PTL reduces OPN protein in U937 cells.** To determine the effects of PTL on transcriptional activity of OPN as a putative cell resistance factors in response to chemotherapy, we investigated protein levels of OPN by Western blotting analysis. The results showed that PTL at concentration of 4 μM (IC25 value for U937) can reduce OPN protein in U937 cells (Fig. 1). This confirms our previous study in which OPN mRNA levels decrease was shown by qRT-PCR [26].

![Fig. 1. Western blotting analysis shows decrease in OPN protein level in PTL-treated U937 cells](image)

**PTL decreases NF-κB/RelB mRNA expression in U937 cells.** NF-κB/RelB gene expression was significantly attenuated in PTL-treated U937 cells (Fig. 2). This finding implies a concurrence between OPN and NF-κB/RelB expression. In the other words, PTL might reduce the expression of both OPN and NF-κB/RelB either by separate mechanisms or in some way related to each other.

![Fig. 2. PTL treatment decreases NF-κB/RelB expression in U937 cells.](image)

**Suppression of OPN with siRNA increases the cytotoxic effects of PTL on U937 cells.** To investigate whether the OPN gene knockdown decreases the cell viability and proliferation after PTL addition, we used optimized OPN siRNA. The PTL treatment subsequently after OPN siRNA addition decreased the cell viability and clonogenic growth compared with the control (without siRNA and PTL treatment) in U937 cells (Fig. 3). These observations imply that OPN plays an important role in the regulation of survival and proliferation of AML cells.

![Fig. 3. Suppression of OPN with siRNA increases the cytotoxic effects of PTL on U937 cells.](image)

**DISCUSSION**

In our previous work concerning PTL effect on OPN gene expression in U937 cells we were faced with OPN reduction [26]. The present study showed that OPN is also attenuated in protein levels in PTL-treated U937 cells. We found that suppression of OPN with siRNA decreased the viability and colony-forming ability of U937 cells in presence of PTL.

When a malignant cell resists to chemotherapeutic agents, the relapse and failure in treatment can occur [27]. Several relatively recent studies have pointed to PTL as a novel antileukemic agent that can selectively eliminate LSCs and progenitor cells [19, 20]. Nonetheless some mediators bestow a resistance to apoptosis advantage upon the PTL-treated cells [28]. The effects of high expression of OPN on leukemogenesis and cell protection from cytotoxic agents have been presented [29]. Besides, the studies on HL-60 cells give evidence that leukemia cells may produce OPN mRNA [8, 30]. Therefore, OPN might be involved in the PTL effects in some hematopoietic malignancies.
We found that the vulnerability of U937 cells to PTL increases when \( \text{OPN} \) gene expression is inhibited. The reductive effect of PTL on OPN expression in U937 cells could be attributable to inhibition of transcription factor AP-1 as known OPN transcriptional activator, alike what has been reported in cystic fibrosis [31]. In addition, the proapoptotic potency of PTL in cancer cells is expressed interfering directly or indirectly with crucial proteins that function as gene transcriptional regulatory units, especially with NF-kB [32, 33]. In our work, PTL could be involved in the gene transcription of \( \text{NF-kB/RelB} \) consistent with \( \text{OPN} \) gene expression mode in U937 cells. There is a number of reports of a NF-κB binding site on \( \text{OPN} \) promoter and the mutual relation between OPN expression and NF-kB activation [34–37].

PTL can induce apoptosis in leukemic cells through additional mechanisms such as PI3K pathway suppression, induction of reactive oxygen species, and activation of stress response proteins [22, 24, 38–40]. We also observed that PTL decreased the mRNA levels of \( \text{AKT} \), \( \text{mTOR} \), \( \beta\text{-catenin} \) and \( \text{PTEN} \) in U937 cells. These genes are oncogenes or tumor suppressor genes that have important role in the control of the cell cycle or apoptosis and they are frequently activated or suppressed in AML [41]. The suppressing effect of PTL on AKT/mTOR activation in malignancies has been already reported [22, 38, 42, 43]. According to UCSC genome browser on human, there are several binding sites of NF-κB in the \( \text{AKT} \) and \( \text{PTEN} \) promoter region that might have been intervened in PTL effects. The interferential role of the transcription factors that may be common for these mediators (STAT3 as an example) could exert subtractive effects of PTL on their transcription. There is an AP-1 binding site in AKT promoter region and with regard to afore-mentioned this suggests a possible route toward AKT transcriptional inhibition by PTL [31, 44–46]. There is an evidence of the inhibitory effect of PTL on the ERK pathway, which in turn activates proto-oncogenic transcription factor TCF employing β-catenin to induce gene expression [31, 47]. Given that PTL is an opponent for AKT/mTOR and subsequently for β-catenin as well as OPN, the levels of its expression might be coincided with them as seen in association of the activation of Akt and OPN with the PTEN activation [48]. The aberrant transcripts of PTEN in U937 have been reported [49], then the lower viability in PTL-treated U937 cells could be attributed to PTEN deficiency the same as in PTEN-deficient myeloma cells being more sensitive to mTOR inhibition with accompanying reduction in viability [50].

In view of the more pronounced reduction of the above mentioned mRNA levels in cells transfected with OPN siRNA in comparison with untreated or PTL-exposed cells, it seems that OPN plays a role in the mechanisms of the transcription of these genes. To our knowledge, no other investigation has been conducted in association between OPN and transcriptional regulation of our studied genes. However, the role of OPN in activation of the intracellular PI3K/Akt signal pathway following binding to avβ3 integrin or CD44 has been described [51–53]. Also, there is a report that OPN induces mTOR phosphorylation at Ser-2448 [37]. Besides, an overall increase in β-catenin protein levels with a resultant transfer of β-catenin to the nucleus subsequent to OPN-induced Akt activation has been suggested [54]. There are others reports implying OPN participation in transcription of vari-

---

**Fig. 4.** PTL and OPN siRNA decrease the mRNA expression of AKT, mTOR, β-catenin or PTEN. The effects of OPN suppression by siRNA on transcription of AKT1, mTOR, β-catenin and PTEN genes, relative to HPRT, were analyzed by quantitative RT-PCR. Three independent experiments were performed (mean ± SD). *\( p < 0.05 \), **\( p < 0.01 \), ***\( p < 0.001 \) (compared with control)
ous genes that can be exerted by multiple pathways including PI3K/AKT, Wnt-β-catenin, P70S6K/mTOR, and IkBα/IKK [37, 54, 55].

In summary, the sensitivity of U937 cells to PTL can be associated with the reduced expression of prosurvival mediators such as OPN, AKT1, mTOR or β-catenin.

ACKNOWLEDGMENT

All authors claim no conflicts of interest or financial involvements with this manuscript. This study was funded by Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine and by Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital.

REFERENCES

37. Ahmed M, Kundu GC. Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB


